The Drug-Induced Cardiotoxicity Website and App

Cyanoacrylate (N-butyl-2-cyanoacrylate-Histoacryl)

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXXI.b

Eye-catcher: Cement (pulmonary) embolism

Publications

Papiamonis NE, Matrella E, Blevrakis EG, Kouroumalis EA

Acute pulmonary embolism following N-butyl-cyanoacrylate endoscopic injection sclerotherapy.

Annals of gastroenterology. 2012;25(3):261

Conway R, Aglan A, O'Connor E

Severe respiratory failure due to embolization of cyanoacrylate sclerosant.

QJM : monthly journal of the Association of Physicians. 2014;107(10):831-2

Alexander S, Korman MG, Sievert W

Cyanoacrylate in the treatment of gastric varices complicated by multiple pulmonary emboli.

Internal medicine journal. 2006;36(7):462-5

van Beek AP, van Erpecum KJ

Fatal N-butyl-2-cyanoacrylate pulmonary embolism after sclerotherapy for variceal bleeding.

Endoscopy. 2005;37(7):687